Fulvestrant combined with exemestane

Fulvestrant combined with exemestane is a treatment option for breast cancer. Fulvestrant is an estrogen receptor antagonist that inhibits the growth of tumor cells by binding to estrogen receptors. Exemestane is an aromatase inhibitor that inhibits the synthesis of estrogen and reduces estrogen levels, thereby inhibiting the growth of breast cancer cells. The combined use of fulvestrant and exemestane can exert a synergistic effect to inhibit the growth of breast cancer cells from two different angles and improve the therapeutic effect. Some studies have shown that fulvestrant combined with exemestane can significantly improve the disease control rate and progression-free survival time of patients with advanced breast cancer, and is well tolerated and safe.